Immuno-Oncology Research

Immuno-oncology research is one of the most dynamic areas of cancer research

Immuno-oncology is considered by some to be one of the most promising areas of research in the world of anti-cancer therapeutics. Aimed at generating a cancer immunotherapy, immuno-oncology manipulates the body’s own immune response to mount an attack against tumor cells.

Updated Cancer research guidebook

Learn how to maximize funding, save time, save precious samples, and more.

Download now

Updated Immuno‑oncology (I‑O) guide

Discover key I‑O research approaches, including checkpoint inhibitor therapy research, CAR T cell therapy research, and cancer vaccine therapy research.

Download now

Recent breakthroughs in immuno-oncology research translate into a paradigm shift with regards to attacking advancing cancer. The benefits of immuno-oncology have resulted in long-lasting tumor regression where surgery, radiotherapy, chemotherapy, and targeted therapy proved less effective.

There are several approaches within immuno-oncology research, including checkpoint inhibitor therapy, adoptive cell therapy (ACT), dendritic cell therapy, and cancer vaccine development. Figure 1 below depicts the adapted cancer-immunity cycle and the stages that can be impacted by discoveries within each research area. Thermo Fisher Scientific strives to provide the most innovative tools and educational assets to advance your immuno-oncology research. The categories below offer access to resources for each immuno-oncology research approach.

Figure 1. Stages of the adapted cancer-immunity cycle [1] can be impacted by I-O approaches such as checkpoint inhibition, CAR T-cell therapy, and cancer vaccines, as indicated by the icons.